Risk in Communities (ARIC) study, Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE IT), A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID), National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II (NEPTUNE II), and Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients with Intermittent Claudication (ICPOP). He has also participated as a member of several data and safety monitoring boards and is editorial director for www.lipidsonline.org. He has published extensively and has spoken nationally and internationally on lipids, atherosclerosis, and inflammation. Dr. Ballantyne’s research interests include the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion. His clinical interests include preventive cardiology, lipids, metabolic syndrome, atherosclerosis, genetics, and coronary artery disease.

Joseph Bonventre, M.D., Ph.D., received his M.D. and Ph.D. (Biophysics) from Harvard University. Dr. Bonventre is the Robert H. Ebert Professor of Medicine and Health Sciences and Technology at Harvard Medical School. He is director of the Renal Division at Brigham and Women’s Hospital. His research involves investigating the mechanisms of cellular and tissue injury and repair, particularly as applied to ischemic injury to the kidney.

H. Bryan Brewer, Jr., M.D., is the director of Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute at Washington Hospital Center in Washington, DC. He was formerly chief of the Molecular Disease Branch at the National Heart, Lung, and Blood Institute (NHLBI) of the NIH, a position he held from 1976 until 2005. Dr. Brewer’s research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinemias. More recently, he has pioneered the use of transgenic mice and rabbits, as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis. Dr. Brewer received his M.D. from Stanford University School of Medicine. After completing his internship and residency in Internal Medicine at Massachusetts General Hospital, he joined NHLBI. He served as a member of the Board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States. As a recipient of the J.D. Lane Investigator Award from the U.S. Public Health Service,

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement